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process was defined as the state function of some system
whose state at a future time can be probabilistically pre-
dicted from its present state, in a way that cannot be im-
proved by taking account of previous states—known as
the Markov property. Nowadays, many economic mod-
els use the Markov technique and are limited by its prop-
erty. The correctness of this approach is questionable, as
will be addressed in the workshop. In an attempt to ad-
here to a well-known technique, many researchers tend
to ignore the memory component inherent to the disease.
Although this major simplification makes the develop-
ment and computation of these models easier, it often de-
parts substantially from reality. Others circumvent the
consequences of the core philosophy behind the tech-
nique and simulate memory by creating tunnel states.
This only provides a partial, suboptimal solution, how-
ever. We feel researchers should urgently shift their focus
to other modeling approaches better suited to the specific
research question. Although more complicated, the devel-
opment of memory-based models is clearly feasible with
today’s computer capabilities, as we will illustrate based
on our own experience.
WMM2
ECONOMIC EVALUATION OF PROSPECTIVE 
MULTINATIONAL CLINICAL TRIALS: A 
MODELING APPROACH
Hux M1, Weinstein M1,2, Torrance G1,3
1Innovus Research Inc., Burlington, ON, Canada; 2Harvard 
School of Public Health, Boston MA, USA; 3McMaster 
University, Hamilton, ON, Canada
WORKSHOP OBJECTIVE: A modeling approach to the
use of data from a multinational clinical trial for eco-
nomic evaluation of a new product in a specific partici-
pating country is described. Treatment effectiveness is es-
timated based on efficacy data using all participating
countries. Costs to a relevant healthcare perspective and
to society are modeled based on clinical response to treat-
ment combined with health resource use in the specific
country of interest. Costs for patients dropping off study
treatment may be estimated from other sources and used
in the model for a more comprehensive estimate of total
costs and consequences.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers involved with the design or conduct of economic eval-
uations related to prospective clinical trials.
In many countries, economic evaluation of new products
is required or has come to be expected by regulatory and
clinical audiences rapidly after product launch. Multina-
tional clinical trials powered to estimate efficacy and
safety against a standard treatment using data from all
countries combined have become common in phase III of
the drug development process. Many researchers are us-
ing this valuable opportunity to collect high quality RCT
data on health resource use, quality of life and patient
preferences. In contrast to efficacy and safety informa-
tion, it may not be possible to directly combine health re-
source use from several countries due to between-country
differences in healthcare systems, treatment practice pat-
terns, and healthcare seeking behavior. We describe the
use of a decision tree model to structure the evaluation
with estimates of treatment efficacy, safety, and resource
use collected from the clinical trial.
WMS1
ESTIMATING MEDICAL COSTS FROM 
INCOMPLETE FOLLOW-UP DATA
Polsky D, Glick H
University of Pennsylvania, Philadelphia, PA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to develop skills in the analysis of cost data
at the patient level when incomplete follow-up or drop-
outs result in censored cost data. We will identify the
conditions when univariate summary data are unbiased
as well as the conditions when various multivariate tech-
niques using regression analysis and survival analysis are
required for unbiased estimates.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers and analysts involved in the methodological and ana-
lytic aspects of pharmacoeconomic studies as well as
those who want to increase their understanding of the lit-
erature of economic evaluation in clinical trials.
As treatment costs are increasingly determined from indi-
vidual level cost data, analysts have become increasingly
aware of the difficulty in characterizing medical costs for
all individuals for comparable durations of time. It is
common for data on resource use and/or costs not to
cover the entire duration of the study. This may be due to
the final design (e.g., rolling admission and a fixed stop-
ping date), limited commitment to the collection of eco-
nomic data, or individuals dropping out of the economic
study or the administrative database. Different models
for analyzing costs should be used depending on the an-
swers to the following questions: Are the dropouts con-
centrated among the most severe patients? Are the rea-
sons for dropouts related to the treatment drug? Could
the dropouts be related to some unmeasured phenome-
non that is correlated with costs? Is death a possibility
among the dropouts? Practical guidance will be provided
for applying the appropriate methods by critically re-
viewing the statistical models for addressing these issues
using a resent AIDS trial as an example.
WMD1
DATA COLLECTION METHODS FOR
RESOURCE UTILIZATION: CHOOSING
THE RIGHT APPROACH
Crawford B, Evans C
MAPI Values, Boston, MA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to develop a deeper understanding of vari-
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ous data collection methods; to provide an interactive fo-
rum for discussing recommendations for the use of each
method; and to discuss the implications that alternative
measurement strategies may have on reported results.
PARTICIPANTS WHO WOULD BENEFIT: This ses-
sion is directed at individuals who are responsible for the
design and conduct of pharmacoeconomic evaluations.
Individuals who need to interpret study results will also
benefit from this workshop.
Pharmacoeconomic studies are often designed without
the appropriate concern for, or justification of, the data
collection method used. Previous research has focused
mainly on what data to collect rather than how to col-
lect the data. This current research focuses on the issue
of study validity through the use of various data collec-
tion strategies. This workshop will discuss the appropri-
ate application of each strategy and provide recommen-
dations for the employment of particular data collection
methods in the context of specific studies. Methodolo-
gies to be discussed include office-based self-administra-
tion, patient diaries, face-to-face interviews (written and
oral), telephone interviews (personal and CATI), and
postal surveys. The research presented here augments
earlier research by informing researchers of potential is-
sues with data collection techniques on resource utiliza-
tion collection.
WMQ1
THE SCHIZOPHRENIA CARE AND ASSESSMENT 
PROGRAM HEALTH QUESTIONNAIRE 
(SCAPHQ): A BRIEF INSTRUMENT TO ASSESS 
OUTCOMES OF CARE IN SCHIZOPHRENIA
Johnstone BM1, Loosbrock DL1, Lehman AF2, Fischer EP3, 
Postrado L2, Delahanty J2, Russo PA4
1Health Outcomes Evaluation Group, United States Medical 
Division, Eli Lilly and Company, Indianapolis, IN, USA; 
2Center for Mental Health Services Research, University of 
Maryland, Baltimore, MD, USA; 3Center for Mental 
Healthcare Research, University of Arkansas for Medical 
Sciences, Little Rock, AR, USA, 4The Medstat Group, 
Washington, DC, USA
WORKSHOP OBJECTIVE: Advances in treatment for
schizophrenia and the development of evidence-based
standards of care demand better methods for population-
based research on this disease and routine assessment of
treatment outcomes in systems of care. The purpose of
this workshop is to introduce the Schizophrenia Care and
Assessment Program Health Questionnaire (SCAPHQ),
a brief instrument to measure the clinical and functional
outcomes of care for schizophrenia. We will describe the
rationale for the instrument, the process of its develop-
ment, and its scope of measurement. We will discuss the
validity of the SCAPHQ in relation to concurrent ad-
ministration of major clinical and functional instruments for
schizophrenia. We will consider applications of SCAPHQ
in longitudinal studies and present results of its use in this
context. The participant will understand potential appli-
cations of the instrument in research and routine assess-
ment.
PARTICIPANTS WHO WOULD BENEFIT: Providers
of care for schizophrenia and researchers with interest in
methods to measure and monitor outcomes of treatment
in actual care settings.
Schizophrenia affects about one percent of the popula-
tion and exacts substantial human and economic costs.
We will discuss the development, validation, and applica-
tions of a new instrument (SCAPHQ) to assess out-
comes of care for this disease in research or routine clini-
cal assessment. We will address measurement of patients’
disease status (symptoms, side effects), generic health sta-
tus, functional status (productivity, social relations, daily
activities, leisure), quality of life, and safety and welfare.
We will evaluate the instrument’s performance with re-
spect to internal consistency, test-retest reliability, and
criterion validity in comparison to existing instruments.
We will discuss use of the instrument to model the effect
of prior period clinical status, medication therapy, and
other patient characteristics on clinical and functional
outcome. Participants with interest in patient-centered
methods for schizophrenia outcomes assessment will ben-
efit from this workshop.
SESSION 2
WPE4
AN ELECTRONIC TOOL FOR EMPIRIC 
ASSESSMENT OF DISEASE RISK, 
CATEGORIZATION OF PATIENTS AT RISK AND 
MONITORING OF OUTCOMES
Ambegaonkar A, Day D, Brandman J, Livengood K, Lubowski 
TJ, Nobles-Knight D, Van Vleet J, Woon J, Yamaga C
Clinical Pharmacy Outcomes Research, Pfizer Inc., New York, 
NY, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop is to present Multiple Disease Risk Assessment
2000 (MDRA 2000), a tool for empiric assessment of
disease risk factors, categorization of patients at risk, and
monitoring of patient outcomes.
PARTICIPANTS WHO WOULD BENEFIT: Health-
care decision-makers and others involved in the process
of monitoring and evaluating patient outcomes.
Identifying patients at risk for disease and providing ap-
propriate care can improve patient outcomes and results
in significant cost reductions to healthcare systems. Mul-
tiple Disease Risk Assessment 2000 provides clinicians
with a valuable tool for performing a systematic analysis
of patients at risk of developing a selected disease, infec-
tion, or medical complication. The tool can identify pres-
ence of key risk factors, serve as a guideline for initiating
a therapeutic intervention, and can help identify factors
